Products & Portfolio (6)
1 discontinued product not shown
ESOMEPRAZOLE MAGNESIUM
esomeprazole magnesium
Post-LOE
ORAL · CAPSULE, DELAYED RELEASE
2023
30
GUAIFENESIN
guaifenesin
Post-LOE
ORAL · TABLET, EXTENDED RELEASE
2017
30
IBUPROFEN
ibuprofen
Post-LOE
SMORAL · SUSPENSION
Cyclooxygenase Inhibitors
2018
30
IBUPROFEN
ibuprofen
Post-LOE
SMORAL · SUSPENSION/DROPS
Cyclooxygenase Inhibitors
2018
30
LEVETIRACETAM
levetiracetam
Post-LOE
ORAL · SOLUTION
mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice. These findings suggest that the interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.
partial-onset seizures in patients 1 month of ageolderepilepsy
2025
30
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
loperamide hydrochloride 2mg, simethicone 125mg
Post-LOE
ORAL · TABLET
2021
30
Open Jobs (0)
No open positions listed yet.
Interview Prep Quick Facts
Portfolio: 7 approved products
Top TAs: Musculoskeletal, Neurology, Respiratory
H-1B (2023): 5 approvals
Portfolio Health
Post-LOE7 (100%)
7 total products
Therapeutic Area Focus
Marketed
Pipeline
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
5
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub